About
Stingray Therapeutics is a clinical-stage biotech developing Vizenpistat (SR-8541A), a small-molecule ENPP1 inhibitor designed to reactivate innate immunity via the cGAS‑STING pathway for cancer immunotherapy; the program is in Phase 1 and Phase 1b/2 trials across multiple solid tumor indications.
Explore Stingray Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.